<i>In vivo</i> studies of a peptidomimetic that targets EGFR dimerization in NSCLC

Shrestha, Leeza; Singh, Sitanshu S.; Parajuli, Pravin; Dahal, Achyut; Mattheolabakis, George; Meyer, Sharon; Bhattacharjee, Joydeep; Jois, Seetharama D.

doi:10.7150/jca.46320



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(20):5982-5999. doi:10.7150/jca.46320 This issue Cite

Research Paper

In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC

Leeza Shrestha¹, Sitanshu S. Singh¹, Pravin Parajuli¹, Achyut Dahal¹, George Mattheolabakis¹, Sharon Meyer¹, Joydeep Bhattacharjee², Seetharama D. Jois^1✉

1. School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201.
2. Biology Program, School of Sciences, University of Louisiana, Monroe, Monroe, LA 71029.

Citation:

Shrestha L, Singh SS, Parajuli P, Dahal A, Mattheolabakis G, Meyer S, Bhattacharjee J, Jois SD. In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC. J Cancer 2020; 11(20):5982-5999. doi:10.7150/jca.46320. https://www.jcancer.org/v11p5982.htm

Other styles

Abstract

Studies related to lung cancer have shown a link between human epidermal growth factor receptor-2 (HER2) expression and poor prognosis in patients with non-small cell lung cancer (NSCLC). HER2 overexpression has been observed in 3-38% of NSCLC, while strong HER2 protein overexpression is found in 2.5% of NSCLC. However, HER2 dimerization is important in lung cancer, including EGFR mutated NSCLC. Since HER2 dimerization leads to cell proliferation, targeting the dimerization of HER2 will have a significant impact on cancer therapies. A peptidomimetic has been designed that can be used as a therapeutic agent for a subset of NSCLC patients overexpressing HER2 or possessing HER2 as well as EGFR mutation. A cyclic peptidomimetic (18) has been designed to inhibit protein-protein interactions of HER2 with its dimerization partners EGFR and HER3. Compound 18 exhibited antiproliferative activity in HER2-positive NSCLC cell lines at nanomolar concentrations. Western blot analysis showed that 18 inhibited phosphorylation of HER2 and Akt in vitro and in vivo. Stability studies of 18 at various temperature and pH (pH 1 and pH 7.6), and in the presence of liver microsomes indicated that 18 was stable against thermal and chemical degradation. Pharmacokinetic parameters were evaluated in nude mice by administrating single doses of 4 mg/kg and 6 mg/kg of 18 via IV. The anticancer activity of 18 was evaluated using an experimental metastasis lung cancer model in mice. Compound 18 suppressed the tumor growth in mice when compared to control. A proximity ligation assay further proved that 18 inhibits HER2:HER3 and EGFR: HER2 dimerization. Overall, these results suggest that 18 can be a potential treatment for HER2-dimerization related NSCLC.

Keywords: NSCLC, HER2, EGFR, dimerization, peptidomimetic

Citation styles

APA

Shrestha, L., Singh, S.S., Parajuli, P., Dahal, A., Mattheolabakis, G., Meyer, S., Bhattacharjee, J., Jois, S.D. (2020). In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC. Journal of Cancer, 11(20), 5982-5999. https://doi.org/10.7150/jca.46320.

ACS

Shrestha, L.; Singh, S.S.; Parajuli, P.; Dahal, A.; Mattheolabakis, G.; Meyer, S.; Bhattacharjee, J.; Jois, S.D. In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC. J. Cancer 2020, 11 (20), 5982-5999. DOI: 10.7150/jca.46320.

NLM

CSE

Shrestha L, Singh SS, Parajuli P, Dahal A, Mattheolabakis G, Meyer S, Bhattacharjee J, Jois SD. 2020. In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC. J Cancer. 11(20):5982-5999.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.